AU5030298A - Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion - Google Patents

Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion

Info

Publication number
AU5030298A
AU5030298A AU50302/98A AU5030298A AU5030298A AU 5030298 A AU5030298 A AU 5030298A AU 50302/98 A AU50302/98 A AU 50302/98A AU 5030298 A AU5030298 A AU 5030298A AU 5030298 A AU5030298 A AU 5030298A
Authority
AU
Australia
Prior art keywords
tnf
alpha
overproduction
mammal
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50302/98A
Inventor
Roy A Black
Jeffrey N. Fitzner
Paul R Sleath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU5030298A publication Critical patent/AU5030298A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU50302/98A 1993-08-23 1998-01-06 Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion Abandoned AU5030298A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US110601 1993-08-23
US18301994A 1994-01-18 1994-01-18
US183019 1994-01-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU75694/94A Division AU687436B2 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion

Publications (1)

Publication Number Publication Date
AU5030298A true AU5030298A (en) 1998-03-05

Family

ID=26808203

Family Applications (2)

Application Number Title Priority Date Filing Date
AU75694/94A Ceased AU687436B2 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion
AU50302/98A Abandoned AU5030298A (en) 1993-08-23 1998-01-06 Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU75694/94A Ceased AU687436B2 (en) 1993-08-23 1994-08-19 Inhibitors of TNF-alpha secretion

Country Status (8)

Country Link
EP (1) EP0715619A4 (en)
JP (1) JPH09503201A (en)
AU (2) AU687436B2 (en)
CA (1) CA2170158A1 (en)
FI (1) FI960803A (en)
NO (1) NO960723D0 (en)
NZ (1) NZ271893A (en)
WO (1) WO1995006031A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0784629T3 (en) 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
EP0824543A1 (en) * 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
CA2217857A1 (en) * 1995-05-10 1996-11-14 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
WO1997009420A2 (en) * 1995-09-05 1997-03-13 Celltech Therapeutics Limited Dna sequences coding for a human metalloproteinase and variants thereof
HUP0003760A3 (en) * 1995-10-05 2001-05-28 Darwin Discovery Ltd Cambridge Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
NZ322553A (en) 1995-11-23 1998-12-23 British Biotech Pharm Metalloproteinase inhibitors
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
PL191366B1 (en) 1996-09-10 2006-05-31 Vernalis Oxford Ltd Cytostatic derivatives of hydroxamic acid
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
AU730308B2 (en) * 1997-06-18 2001-03-01 Rockefeller University, The Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
EP1021173A1 (en) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Use of csaid?tm compounds for the management of uterine contractions
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
WO2000018361A2 (en) * 1998-09-30 2000-04-06 The Procter & Gamble Company Method of treating hair loss using sulfonamides
BR9914197A (en) * 1998-09-30 2001-07-03 Procter & Gamble Hair loss treatment process with the use of ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
JP2002534440A (en) * 1999-01-13 2002-10-15 ヨマー、ファルマカ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Use of 3-isoxazolidinone and hydroxylamic acid for the treatment of infectious diseases
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
WO2002028829A2 (en) * 2000-09-25 2002-04-11 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (en) 2001-12-20 2003-08-21 Schering Corp COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
BR112021006407A8 (en) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med use of egfr inhibitors for keratoderms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986003747A1 (en) * 1984-12-19 1986-07-03 Ciba-Geigy Ag New carbonic acid esters
FR2609289B1 (en) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger NOVEL COMPOUNDS HAVING ACTIVITY OF COLLAGENASE INHIBITORS, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
AU2228292A (en) * 1991-06-14 1993-01-12 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives

Also Published As

Publication number Publication date
AU687436B2 (en) 1998-02-26
FI960803A0 (en) 1996-02-22
JPH09503201A (en) 1997-03-31
FI960803A (en) 1996-04-22
AU7569494A (en) 1995-03-21
NO960723L (en) 1996-02-23
WO1995006031A1 (en) 1995-03-02
CA2170158A1 (en) 1995-03-02
NZ271893A (en) 1997-11-24
EP0715619A4 (en) 1997-03-19
NO960723D0 (en) 1996-02-23
EP0715619A1 (en) 1996-06-12

Similar Documents

Publication Publication Date Title
AU5030298A (en) Method of treating a mammal having a disease characterised by an overproduction or an upregulated production of TNF-alpha using biologically active compounds as inhibitors of TNF-alpha secretion
AU639500B2 (en) Method for production of acrylic acid
CA2173963A1 (en) Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
AU7023191A (en) Method for fabrication of implantable electrode
AU3067995A (en) Method for treatment of sleep apnea
AU633274B2 (en) Method for controlling the growth of non-osseous non-cartilaginous solid connective tissue
AU2674797A (en) Method of treating movement disorders by brain infusion
AU7973691A (en) Automated method for the manufacture of small implantable transponder devices
EP0617457A3 (en) Method for production of wafer.
AU3198699A (en) Method for the treatment of joint diseases characterized by unwanted pannus
AU4891696A (en) Method for production of alkylhalosilanes
AU7626991A (en) Combination of pravastatin and fibric acid derivative, and method for treating dyslipidemia using such combination
AU8532691A (en) Method for treating corneal endothelial wounds
AU7249494A (en) Method for increasing the capacity of sewage treatment plant
AU5926090A (en) A method for biological treatment of wastewater
SG42986A1 (en) Method for production of methacrylic acid
AU3579195A (en) Process for manufacturing clavulanic acid salt
AU1727499A (en) Method for treating fibroproliferative disorders by inhibitors of protein hydroxylation
AU4976599A (en) Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
AU6153094A (en) Plant tissue culture method for taxol production
AU6771190A (en) Method for treatment of waste water from (meth)acrylic acid production plant
AU5831800A (en) Method for the control of the manufacturing process of polyols
AU3269197A (en) Method of treating a plant disease
AU8113091A (en) Method of treatment of allergic conjunctivitis
AU8752991A (en) Method of treating auto-immune diseases using gallium compounds

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application